Veeva Systems Inc. reports developments in cloud software, data, AI, and consulting for the life sciences industry. Company news commonly covers adoption of the Veeva Vault Platform, including Development Cloud, Quality Cloud, Commercial Cloud, Data Cloud, Vault CRM, and Veeva MedTech applications for clinical, regulatory, quality, commercial, and medical operations.
Updates also include customer standardization projects with pharmaceutical, biotechnology, medical device, and diagnostics companies; product and data offerings such as Link Key People and Veeva AI; fiscal results and subscription revenue trends; and corporate actions such as acquisitions, including the completed purchase of Ostro as a life sciences brand engagement platform.
Veeva Systems (NYSE: VEEV) has expanded its partnership with LEO Pharma, enhancing engagement with medical communities through Veeva Link for Key People. This tool aims to foster scientific discussions and improve patient care by allowing LEO Pharma's teams to access real-time intelligence and insights. The collaboration is set to advance new dermatology treatments every 2-3 years. Veeva Link integrates with Veeva CRM to offer comprehensive insights, positioning LEO Pharma to effectively engage with key scientific leaders in dermatology.
Veeva Systems has launched Veeva Data Cloud, a suite of cloud data applications designed to enhance commercial excellence in the life sciences sector. This platform incorporates Veeva OpenData, Veeva Link, and Veeva Compass, enabling seamless interaction across sales, medical, and marketing teams through a common data architecture. It provides real-time intelligence and extensive customer reference data, with plans to expand operations to over 100 countries by year-end 2023. The initiative aims to ensure data is always current and foster collaboration for improved patient access to products.
Veeva Systems (NYSE: VEEV) has launched four new applications under its Veeva Link product suite to provide real-time intelligence for medical and commercial teams. These include Veeva Link for Key Accounts, Veeva Link for Scientific Awareness, Veeva Link for Medical Insights, and Veeva Link+. Designed for key account management, these tools aim to improve engagement with scientific experts and enhance insights across various healthcare areas. The new applications are part of Veeva's commitment to delivering data-driven solutions in the life sciences industry.
Veeva Systems announced that Bristol Myers Squibb has successfully implemented Veeva Vault CTMS globally within 20 months, replacing legacy systems from both companies. This integration aims to streamline clinical trial management, enhancing efficiency in bringing medicines to patients. Bristol Myers Squibb highlighted the expansion of their partnership with Veeva in R&D, citing the significance of this milestone in the largest IT integration project in pharma history. Veeva's Vault CTMS facilitates advanced trial execution capabilities, marking a crucial step in modernizing clinical trial processes.
Boehringer Ingelheim has selected Veeva Development Cloud to enhance the efficiency of its drug development processes. This partnership aims to create a unified technology framework for better collaboration and faster delivery of innovative therapies. With the support of Veeva's applications, Boehringer Ingelheim intends to streamline clinical, regulatory, and quality operations, contributing to its 'One Medicine Platform' initiative. The focus is on reducing complexity and fostering a digital culture to address unmet medical needs.
Veeva Systems reported strong financial results for the fourth quarter and fiscal year ending January 31, 2022. Total revenues for Q4 reached $485.5 million, a 22% increase year-over-year. Subscription services revenues grew by 23% to $395.7 million. Operating income rose 21% to $119.7 million, while non-GAAP net income increased 17% to $147.0 million. For fiscal 2022, revenues totaled $1,850.8 million, a 26% increase, with net income up 12% to $427.4 million. The company provided guidance for fiscal Q1 2023 with total revenues expected between $494 million and $496 million.
Veeva Systems (NYSE: VEEV) announced the inaugural Veeva TMF Innovation Forum to be held online on March 10, 2022. The event will gather over 250 experts in trial master file (TMF) management to discuss advancements in digital clinical trials. Key themes include the role of TMF as a strategic asset, leveraging artificial intelligence for process automation, optimizing outsourcing models, and meeting new regulatory requirements. The forum aims to enhance clinical strategy and enable a connected clinical ecosystem.
Summary not available.
Veeva Systems announced that Idorsia Pharmaceuticals has expanded its use of the Veeva Vault Clinical Suite to include Vault CDMS for electronic data capture (EDC) and coding. This collaboration allows Idorsia to speed up its clinical trials by utilizing a modern data management system to enhance study execution and management. The cloud-based Vault CDMS will enable Idorsia's clinical teams to independently build studies and make mid-study amendments efficiently, streamlining trial content and data management.
Veeva Systems reports significant adoption of its Vault PromoMats platform by over 300 emerging and mid-size biopharmaceutical companies globally, with more than 40 new clients in the U.S. in the past year. This software aids in streamlining medical, legal, and regulatory review processes and managing digital assets efficiently. The service is designed to support the growing demand for rapid content generation crucial for healthcare professionals. Industry leaders express satisfaction with the platform's capability to enhance compliance, visibility, and efficiency during product launches.